



CNMV
Markets Directorate General
C/ Edison núm. 4
28006 Madrid

Madrid, 23 March 2026

In accordance with article 227 of the Spanish Securities Markets and Investment Services Act (*Ley de los Mercados de Valores y de los Servicios de Inversión*), approved by Law 6/2023, of 17 March, and concordant provisions, is hereby reported the following

OTHER RELEVANT INFORMATION

The Executive Committee of Pharma Mar, S.A., as authorized by the Company's Board of Directors, has decided today to implement the Plan of delivery of shares of the treasury stock of Pharma Mar approved by the General Shareholders' Meeting held on 18 June 2025 (item eight on the Agenda), authorizing the Board of Directors (or the Executive Committee or director or person delegated by the Board) to deliver up to a maximum of 41,000 shares. This Plan is intended exclusively for employees and officers of the Pharma Mar Group in order to promote their participation in the share capital and encourage their permanence in the Group, and under no circumstances may the members of the Board of Directors of Pharma Mar, S.A. be eligible as beneficiaries, even if they hold executive positions in any Group companies.

The essential conditions established for free delivery of the shares are specified below:

- Share lockup system. A lockup system shall be established for the shares distributed to the prevent disposal thereof. This lockup system shall likewise apply to those shares acquired by the beneficiary free of charge and which by means of any corporate transaction have their origins in previously held shares of this type.

The lockup period shall remain in force for three years ("Loyalty Period") from the time of effective delivery of the shares.

Notwithstanding the above, a portion of the shares shall be unblocked a year and half after delivery of the shares; in particular, the lockup shall be lifted from the number of shares equal to total shares distributed divided by two. The shares distributed shall enjoy full political and economic rights.

- Condition subsequent for distribution of shares. Delivery of the shares to each beneficiary is subject to a condition subsequent, which shall be deemed met in the case of voluntary resignation, fair dismissal of the beneficiary or leave (excluding in the case of leave covered by Law 39/1999, of 5 November, on the promotion of employee work-life balance, or by Organic Law 3/2007, of 22 March, on effective gender equality, in which case the Loyalty Period shall be extended for the length of the leave), provided said circumstances arise prior to the end of the Loyalty Period. In the event of termination of the employment relationship between a beneficiary and its employer for reasons other than the above, the Loyalty Period shall be deemed fulfilled, unless the employment relationship was terminated so that a new relationship could be established between the beneficiary and another Pharma Mar Group company.

The shares subject to the condition subsequent will be those that should have remained locked up throughout the Loyalty Period (i.e. those that should, in theory, have remained locked up for three years). Fulfilment of the condition will not have retroactive effects.

Once the condition subsequent has occurred, the shares affected by it must be returned via the same acquisition procedure to Pharma Mar, S.A. or, by request thereof, to the subsidiary employing the beneficiary.

In accordance with the foregoing, the Executive Committee has agreed to deliver shares for a total value of €982,294.84 with a share reference value equal to the lower of: a) the weighted average change in the share price of Pharma Mar, S.A. on the continuous market for today 23 March 2026; b) the simple average change in the daily weighted average change in the share price of Pharma Mar, S.A. on the continuous market for the previous month (i.e. between 23 February 2026 and 23 March 2026, both inclusive). The share value calculated in this manner shall be used exclusively for determining the number of shares to be delivered to each beneficiary, which will under no circumstances exceed €12,000 per beneficiary. This value therefore does not constitute a price of any kind.

The reference value was finally established at €81.5724, corresponding to the simple average change in the daily weighted average change in Pharma Mar's share price on the continuous market for the previous month, as this amount was less than the weighted average change in Pharma Mar's share price on the continuous market for today 23 March 2026, which is equal to €85.6625.

Once the final reference value has been established, the total number of shares to be delivered to the beneficiaries was finally established at 12,042 shares (0.067% of share capital).

The shares shall be delivered via change in ownership which is expected to take place in the coming days.